| MRC Technology to manage intellectual property for AICR |
18 November 2011 |
| MRC Technology to oversee and manage intellectual property arising from AICR-funded projects. Read in full |
 |
|
| 1st patient treated with BAN2401 |
6 September 2010 |
| First Alzheimer’s patient treated with BAN2401, a novel antibody targeting the neurotoxin believed to cause Alzheimer’s disease. Read in full |
|
|
| MRC Technology enters into an exclusive license agreement With Genentech |
12 July 2010 |
| MRC Technology and Genentech enter into agreement for series of small molecule drug candidates. The first such programme to come out of MRC Technology.. Read in full |
|
|
| “Skills Swap” to exploit expertise for patient benefit |
7 July 2010 |
| Cancer Research Technology and MRC Technology to ‘swap’ medical discoveries to accelerate the translation of early scientific research into patient benefit.. Read in full |
|
|
| AstraZeneca and MRC Technology form strategic alliance in discovery research, utilising shared compound libraries |
5 July 2010 |
| AstraZeneca share 100,000 compounds with MRC Technology. Read in full |
|
|
| O2h provides multi-FTE -synthetic chemistry services to MRCT |
16 February 2010 |
| O2h will provide multi-FTE -synthetic chemistry services to the drug discovery programmes at MRC Technology. Read in full |
|
|
| MRCT's call for targets |
4 February 2010 |
| Medical Research Council Technology’s Centre for Therapeutics Discovery opens its first ‘Call for Targets’ in an effort to develop drugs in areas of serious unmet need. Read in full |
|
|
| Collaboration between Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg and MRCT |
12 January 2010 |
| MBM ScienceBridge GmbH negotiates License Agreement between the Georg-August-University Göttingen, Universitätsmedizin, the University of Regensburg, and the UK’s Medical Research Council Technology for a new therapy of inflammatory and immune disease. Read in full |
|
|
| Bicycle Therapeutics is new MRC spinout |
6 October 2009 |
| Bicycle Therapeutics Ltd, a new Medical Research Council (MRC) spin-out, seeking to merge best aspects of small molecules and biologics, secures seed funding from top venture capital firms. Read in full |
|
|
| DiscoveRX GSK and MRCT collaborate to deorphanise GPCRs |
23 September 2009 |
| Industry and academia team up in three-way collaboration to identify natural substances that can bind to orphan G protein-coupled receptors.
Findings could lead to new targets for drug discovery. Read in full |
|
|
| MRC scientists advance understanding of cell death |
13 August 2009 |
| Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells are prompted to die.. Read in full |
|
|
| Centre for Therapeutics Discovery |
2 April 2009 |
| MRC and MRC Technology announce new centre for the discovery of novel drugs. Read in full |
|
|
| Heptares secures funding |
24 February 2009 |
| Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets. Read in full |
|
|
| UK Drug Discovery Consortium symposium |
23 February 2009 |
| 1st Annual Symposium of the new UK Drug Discovery Consortium announced for March 11th 2009. Read in full |
|
|
| MRCT Licence Rights to Develop Potential Novel Immunotherapy |
27 January 2009 |
| The Medical Research Council (MRC) & MRC Technology (MRCT) have signed exclusive License and Research Collaboration agreements with Centocor, Inc., which is now known as Centocor Ortho Biotech Inc., for the development of a novel immunotherapy targeting r. Read in full |
|
|
| MRCT and Biolex Therapeutics complete successful collaborations |
14 July 2008 |
| MRC Technology and Biolex Therapeutics successfully complete
collaboration to humanize a novel antibody targeting CD20. Read in full |
|
|
| Intellect Neurosciences and MRCT reach antibody milestone |
25 June 2008 |
| Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) reach important milestone in generating an Alzheimer’s therapeutic antibody. Read in full |
|
|
| Development Gap Fund extended |
8 June 2008 |
| MRC Technology given £6 Million to increase the commercial potential of early stage science. Read in full |
|
|
| How malaria parasites escape blood cells |
14 December 2007 |
| The way out: how malaria parasites escape the red blood cell. Read in full |
|
|
| Intellect Neurosciences and MRCT to humanize antibodies for AD |
5 September 2007 |
| Intellect Neurosciences, Inc and Medical Research Council Technology (U.K.) enter into agreement to humanize two monoclonal antibodies for the treatment of Alzheimer’s Disease. Read in full |
|
|